Flora’s Kiss Blog

When Your Body’s First Responders Won’t Stand Down: A Deep Dive into Mast Cell Activation Disease

October 2026  |  Published ahead of International Mastocytosis and Mast Cell Diseases Awareness Day, 20 October

If you have ever flushed bright red in a warm room, broken out in hives from the rub of a seatbelt, felt your heart race and your head go foggy after a meal, or reacted to a perfume someone wore three seats away, and then been told your tests are “all normal”, this piece is for you.

Mast Cell Activation Disease (MCAD) is the name for a family of conditions in which mast cells, a type of immune cell found throughout the body, release their chemical messengers too easily, too often, or in the wrong amounts.^1,2 The family is broad. It includes a toddler with itchy brown spots that swell when rubbed, an adult whose bone marrow holds too many mast cells, a person whose first clue was a severe reaction to a bee sting, someone with hives that have come and gone for months, and someone who has had anaphylaxis with no cause ever found. Because mast cells live in almost every tissue, the effects can reach the skin, gut, heart, lungs, bladder, bones and brain, which is why so many people spend years bouncing between specialists before anyone connects the dots.^3,4

This deep dive walks through each member of that family in turn: what it is, who it affects, how it is diagnosed and how it is managed. It then looks at the experiences they share, from whole-body symptoms and flare triggers to everyday strategies and where people in South Australia and beyond can find support. Like our earlier pieces on cold urticaria and the skin’s sensory receptors, it is written with adults front of mind as well as children. Apart from many childhood cases of skin-only mastocytosis, most of these conditions are not something people grow out of.

Disease, Syndrome, Disorder: Getting the Words Right

The terminology here genuinely confuses patients and clinicians alike, so it is worth slowing down.³

• Mast cell activation is a normal process. Every time you get a mosquito bite or a sneeze in pollen season, mast cells are doing their job.³
• Mast Cell Activation Disease (MCAD), sometimes called mast cell activation disorder, is the umbrella term. It covers the whole group of conditions in which mast cell activation becomes a problem in itself.^2,3,5
• Under that umbrella sit conditions where the body makes too many mast cells (mastocytosis), conditions where the mast cells carry the same kind of genetic change seen in mastocytosis, but not enough to meet its criteria (monoclonal MCAS), an inherited trait that affects tryptase (hereditary alpha-tryptasemia), conditions where normal mast cells are overreacting to something else (secondary disorders, such as allergy and chronic hives), and conditions with no cause found (idiopathic disorders).^3,6
• Mast Cell Activation Syndrome (MCAS) is a specific diagnosis with its own criteria. It can occur on its own or alongside several of the conditions above.^1,3

Put simply: MCAS is one important part of the picture, but it is not the whole picture. Researchers have described mast cell disease as an iceberg, with rare mastocytosis visible at the top and a much larger body of mast cell activation disease underneath.⁵

Everyone with MCAS has a mast cell activation disease. Not everyone with a mast cell activation disease has MCAS.

A map of the family

The major international expert group (the European Competence Network on Mastocytosis and the American Initiative in Mast Cell Diseases) published a classification in 2022 that groups these conditions together, including a category for people whose symptoms fit mast cell activation but who do not meet full MCAS criteria.² The Australasian Society of Clinical Immunology and Allergy (ASCIA) groups them as primary, secondary and idiopathic.³

Meet the Mast Cell

Mast cells are long-lived immune cells that sit in connective tissue, particularly at the body’s borders with the outside world: skin, airways, gut lining, and around blood vessels and nerves.^3,8 They are built to be first responders. They help heal wounds, defend against parasites and bacteria, and regulate blood vessels.³

Inside each mast cell are granules packed with chemical messengers, called mediators. These include histamine, tryptase, heparin, prostaglandins, leukotrienes and a range of cytokines.^3,9 Some estimates put the number of different mediators in the hundreds.¹⁰ When a mast cell is triggered, it releases its stored chemicals quickly, and goes on making others over the following hours.

Mast cells can be triggered through the classic allergy pathway (IgE antibodies), but also through many non-allergy routes: heat, pressure, friction, infections, certain medicines, hormones, stress chemicals and more.³ This is important, because it explains why someone can react strongly to something and yet show nothing on standard allergy testing.

The Family in Detail

Cutaneous mastocytosis: mostly a condition of childhood

In cutaneous mastocytosis, extra mast cells collect in the skin only. It is the most common form of mastocytosis in children, and in most children it appears before the age of two, often in the first six months of life.¹¹ In adults, mastocytosis is estimated to affect around 10 to 13 people in every 100,000.¹¹

There are three main forms:¹¹

• Maculopapular cutaneous mastocytosis (once called urticaria pigmentosa) is the most common: brown spots or patches. In children these are often larger and varied in size (the “polymorphic” type); smaller, uniform spots (the “monomorphic” type) are more typical of adults.
• Mastocytoma is a single lump or patch, or up to three, usually about 1 to 10 cm across, and common in infants.
• Diffuse cutaneous mastocytosis is rare and the most severe form, with mast cells spread through the whole skin.

A hallmark is Darier’s sign: when a spot is rubbed, it reddens and swells like a hive.¹¹ Children may also have itch, flushing, tummy pain and diarrhoea, and infants can develop blisters, which usually settle after two to three years of age. Severe reactions, including anaphylaxis, are uncommon and occur mostly in children with extensive skin involvement, blistering or high tryptase levels.^11,12

The outlook is often good. Most cases clear or improve around puberty; ASCIA estimates 67–80% resolve by early adulthood.^6,11 When the condition begins after the age of two, or the spots are of the smaller, uniform kind, it is more likely to persist into adult life, and some of these people are later found to have systemic mastocytosis.^11,13 It is worth noting that the KIT D816V gene change, found in most adults with mastocytosis, is found in only about a third of children.¹¹

Systemic mastocytosis: mostly a condition of adulthood

In systemic mastocytosis (SM), abnormal (clonal) mast cells build up in the bone marrow and often in other organs, sometimes including the skin.⁶ It is mostly diagnosed in adults, and more than 90% of adult cases involve the KIT D816V gene change.^3,6 Many adults have the small brown skin spots described above, but some have no skin signs at all, which can make the diagnosis easy to miss.^11,14

The World Health Organization divides SM into subtypes according to how much the disease is affecting the body:^15,16

A third, very rare form of mastocytosis, mast cell sarcoma, is a solid tumour made of malignant mast cells.⁶

Day-to-day symptoms come mostly from mediator release: flushing, itch, tummy cramps and diarrhoea, brain fog, fatigue and bone pain, with anaphylaxis a real risk for some.^15,17 Two features set SM apart from many other members of the family:

• In a French study of 75 adults with SM, 31% had osteoporosis and 17% had a fracture in the spine; nearly half had some form of bone involvement.¹⁹ This is why bone health is an important part of SM care.
• Insect stings. People with venom allergy are nearly ten times more likely to be diagnosed with mastocytosis than would be expected, and sting reactions in people with mastocytosis can be severe.²⁰

Monoclonal MCAS and the sting connection

Some people have mast cells carrying the same kind of clonal marker seen in SM (such as KIT D816V, or the CD25 marker in the bone marrow) but do not meet full criteria for mastocytosis. This is called monoclonal mast cell activation syndrome (MMAS). People with MMAS have mast cell activation symptoms but no skin lesions.^3,21

Severe insect sting reactions are a key clue. In an Italian study of 22 people who had anaphylaxis with a drop in blood pressure after a sting, no skin lesions and a normal baseline tryptase, 17 were found to have a clonal mast cell disorder on bone marrow testing: 16 with indolent SM and one with MMAS. A reaction with low blood pressure but without hives or swelling was the most useful warning sign.¹⁴ TAMS notes that a diagnosis of MMAS should be reassessed if full criteria for SM are later met.²¹

Hereditary alpha-tryptasemia: a common inherited trait

Hereditary alpha-tryptasemia (HαT) is an inherited genetic trait in which a person has extra copies of the gene for alpha-tryptase, so their baseline tryptase level runs higher than usual.^6,22 It is common, affecting roughly 5–7% of people of Western ancestry, and it runs in families: when one parent carries it, each child has a 50% chance of inheriting it.^7,23

Most people with HαT have no symptoms.^3,7 In others, it appears to act as a risk factor rather than a disease in itself:

• In a large 2021 study, HαT was found in about 5–6% of healthy volunteers but in 12% of people with systemic mastocytosis and 17% of people with idiopathic anaphylaxis. It was linked to the most severe grade of sting anaphylaxis, and people with SM who also had HαT were much more likely to have had anaphylaxis.²⁴
• In a smaller Austrian clinic study, more than half of people with HαT had a history of anaphylaxis, mostly mild, and the trait was not linked to the most severe reactions.²⁵ The evidence on severity is still mixed.
• Links with gut symptoms, brain fog and other complaints have been reported, but TAMS notes that these need more research before they can be confirmed.^7,22

TAMS also describes a proposed label, “HαT-associated MCAD”, for people who have an established mast cell activation disease and HαT together. It describes the combination rather than replacing the main diagnosis.²¹

Secondary mast cell disorders: normal mast cells, pushed into action

In secondary disorders, the mast cells develop normally and are usually normal in number, but something else keeps triggering them.³ This is the most familiar corner of the family, and it includes:

• Allergic reactions and anaphylaxis. Classic allergies to foods, venoms and medicines work by switching on mast cells through IgE antibodies. Some reactions to medicines, such as certain opioids, switch them on directly without IgE.³
• Chronic spontaneous urticaria (CSU). Hives, with or without swelling (angioedema), several times a week for six weeks or more, with no known cause.²⁶ CSU affects about 1–3% of people and is driven by mast cell activation of an autoimmune kind. It is not an allergy, and it does not carry a risk of anaphylaxis.²⁷ Stress, pressure on the skin, infections and anti-inflammatory pain relievers can make it worse.²⁷ That does not make it harmless. Angioedema occurs in roughly 30–45% of people with CSU,²⁸ and sometimes it affects the tongue or throat: in an Italian study of 34 people with CSU and angioedema, 15% had swelling of the throat or voice box.²⁹ Swelling in these areas can make breathing difficult, so it is a medical emergency in its own right.^30,31
• Physical (inducible) urticarias. Hives set off by a physical trigger such as cold, heat, sunlight, vibration, pressure, or rubbing and scratching of the skin.³² Our earlier deep dive on cold urticaria looks at one of these in detail.
• Secondary MCAS. When an identifiable condition, most often an allergy, drives recurrent, multi-system episodes that meet MCAS criteria.²¹

ASCIA notes an interesting pattern: chronic hives and angioedema are common in secondary disorders, but not common in primary disorders such as systemic mastocytosis, where flushing, low blood pressure, cramping, diarrhoea and a racing heart are more typical.³

Idiopathic disorders: when no cause is found

Idiopathic anaphylaxis is a rare condition in which a person has anaphylaxis with no trigger ever identified. It is diagnosed only after other causes have been carefully ruled out, using tests such as skin prick testing, specific IgE blood tests, food or medicine challenges and tryptase.³³ Specialists may also consider clonal mast cell disorders and hereditary alpha-tryptasemia, which in one study was about three times more common in people with idiopathic anaphylaxis than in healthy volunteers.^3,24

Idiopathic MCAS is diagnosed when someone meets the criteria for MCAS but no clonal disorder, allergy or other cause is found. The label can change if a cause is identified later.²¹

Mast cell activation syndrome: the syndrome itself

MCAS can be primary (monoclonal), secondary or idiopathic, as above.^3,21 What makes it a syndrome is a specific pattern: recurrent episodes of mast cell symptoms in at least two body systems, objective evidence of mediator release during an episode, and a response to treatment.¹ It is also the member of the family most debated among specialists, and the diagnosis section below explains why.

People can, and often do, have more than one condition at once. TAMS describes “combined MCAD”, where a clonal disorder such as SM or MMAS exists alongside a secondary driver such as an allergy.²¹ The most severe reactions tend to occur in these combined forms, for example when clonal mast cells, an IgE allergy and sometimes HαT are all present.³⁴

How Mast Cell Activation Disease Presents

There is no single symptom that is specific to mast cell disease.³ What tends to point towards it is a pattern: symptoms that arrive in episodes, involve two or more body systems at the same time, and ease between episodes or with mast cell–directed treatment.^1,35

Many people describe a background of everyday symptoms with bigger flares on top. The strict diagnostic criteria for MCAS focus on the flares, which is part of why diagnosis can be contentious.³ In one large US cohort of people diagnosed with MCAS, the median age at diagnosis was 49, while symptoms had often begun decades earlier; reflux, fatigue and dermatographism (skin that raises welts when stroked) were the most common findings.⁴ Clinic studies in the US and Europe show that most people diagnosed with MCAS are women: in a German study of 66 people with MCAS, 83% were women, with an average age of 44.^4,36

Across the whole body

The brain: why fog and mood are part of the picture

Mast cells are found in the brain itself, including next to the blood-brain barrier, the protective lining that controls what crosses from the bloodstream into brain tissue.⁸ Researchers describe brain mast cells as first responders that can amplify inflammation and influence how permeable that barrier is.⁸ Histamine is also a neurotransmitter, involved in wakefulness and attention.

Stress hormones add another layer. Corticotropin-releasing hormone, a key stress hormone, can activate mast cells, and laboratory and animal research links stress-driven mast cell activity with neuroinflammation and changes in cognition.⁴² This is one plausible reason why emotional stress is so often reported as a trigger, and why flares can feel like they hit thinking and mood as much as the body.

In a French study of 139 adults with mastocytosis, 55% reported headaches, 54% irritability, 52% memory loss and 40% difficulty concentrating; depression was found in 49% of those assessed, and one in four said the condition had affected their working life.⁴⁰ A survey of 180 people with mast cell disorders found that almost two-thirds had clinically meaningful depressive symptoms, closely tied to the physical symptom burden.⁴¹

An honest caveat: brain fog, fatigue and anxiety are common to many conditions, and on their own they do not point to a mast cell problem.³⁵ They become more meaningful when they travel with skin, gut, airway or circulation symptoms in the same episode.

An emerging question: hEDS and the blood-brain barrier

Some researchers have asked whether people with hypermobile Ehlers-Danlos syndrome (hEDS) might have a leakier blood-brain barrier. A 2024 review proposed that connective tissue changes in hEDS, together with mast cell chemicals such as histamine and tryptase, could weaken the barrier, but it drew mainly on animal studies.⁴³ A 2025 review of brain and thinking changes in EDS agreed this is possible, but stated plainly that direct evidence of blood-brain barrier problems in EDS is currently absent, and called for studies to test it.⁴⁴

Please read this as an emerging, unproven idea, not an established finding. No study has yet measured blood-brain barrier leakiness in people with hEDS. It is a question worth watching, and one that may help explain experiences many people describe, but the research has not caught up yet.

The heart and circulation

Mast cell mediators act directly on blood vessels, widening them and making them leakier.^3,10 That can mean sudden drops in blood pressure, a compensating rush of heart rate, and the light-headed, about-to-faint feeling many people describe.¹⁰ In severe reactions this escalates into anaphylaxis, which is a medical emergency.

The gut

Mast cells are plentiful in the lining of the gut.⁸ Gut symptoms are among the most common complaints across the family, and cramping and loose stools in particular often mimic irritable bowel syndrome.³⁷ A 2024 gastroenterology review noted that scopes and biopsies are not used to diagnose MCAS itself, but are important for ruling out other conditions, such as inflammatory bowel disease.^3,37

The throat: when it feels like choking

A choking feeling can come from several different places, and one of them is an emergency.

• Throat swelling in a severe reaction. In anaphylaxis, the throat and voice box can swell, causing throat tightness, difficulty talking, a hoarse voice or noisy breathing (stridor).⁴⁵ The international MCAS criteria list this kind of upper-airway involvement among the typical signs of mast cell mediator release.^1,3 It can happen in any member of the family that causes anaphylaxis, including mastocytosis, MCAS and allergy, and it needs adrenaline straight away.⁴⁵
• Swelling of the lips, tongue or throat (angioedema). This can come with chronic hives as well as with allergic reactions.^26,30 Chronic spontaneous urticaria is not linked to anaphylaxis,²⁷ but that should not be mistaken for safety. Swelling of the tongue or throat can be just as dangerous, because it can cause difficulty breathing. ASCIA advises that severe throat swelling needs early medication and immediate transfer to hospital by ambulance, and an emergency medicine review warns that airway angioedema can be fatal.^30,31 In the Italian study above, 15% of people with CSU and angioedema had swelling of the throat or voice box.²⁹
• Not all angioedema is the same. Some angioedema is driven not by mast cells and histamine but by a different chemical, bradykinin. This includes swelling caused by ACE inhibitor blood pressure medicines and hereditary angioedema, a rare genetic condition. ASCIA notes that ACE inhibitor swelling usually affects the face, tongue and throat, is not itchy, and is not an allergic reaction. Bradykinin-type swelling is unlikely to respond to antihistamines, steroids or adrenaline and needs specific treatments, so it is important to know which kind you have.^30,31
• Everyday throat symptoms. Extra mucus, a constant need to clear the throat and a sense of the airway narrowing are all described in mast cell conditions.^38,39 Reflux, one of the most common problems in people diagnosed with MCAS,⁴ can also cause a sore throat, frequent throat clearing, coughing or choking spasms at night, and a lump-in-the-throat feeling.⁴⁶ These are usually uncomfortable rather than dangerous, but they are worth raising with your doctor.
• A condition that can look similar. In vocal cord dysfunction, the vocal cords close together when a person breathes in, causing throat tightness, breathlessness, noisy breathing, coughing or voice changes. ASCIA notes it can be confused with anaphylaxis or asthma, and lists it among the conditions to rule out when mast cell disease is suspected. It is not an allergic condition. It is diagnosed with laryngoscopy (a camera view of the vocal cords), sometimes alongside breathing tests to rule out asthma, and it is treated differently, for example with speech therapy and breathing techniques. Reflux can be one of its triggers.^3,47

How anaphylaxis can kill, and why every first-aid step matters

Throat swelling is the danger most people picture, but anaphylaxis can kill in other ways too, sometimes with no swelling, hives or rash at all. Understanding the reasons behind each first-aid step can stop a well-meaning person from making a dangerous decision in the moment.

• Shock: when blood pressure collapses. Mast cell chemicals widen blood vessels throughout the body and make them leak. Fluid moves out of the bloodstream into the tissues, and the heart’s pumping can weaken too. Blood pressure can then fall so far that the heart and brain do not get enough blood, and the heart can stop.⁴⁸
• The lungs: when the airways close from below. The airways inside the chest can tighten and become blocked with thick mucus, starving the body of oxygen, much like a severe asthma attack.⁴⁸ People who have both a food allergy and asthma are at particular risk: fatal and near-fatal reactions are strongly associated with that combination.⁴⁸
• The warning signs can be missing. Sudden collapse can sometimes happen before any skin signs appear.⁴⁸ This is common in mastocytosis: in the sting study described earlier, a drop in blood pressure without hives or swelling was the key clue.¹⁴ No rash does not mean no anaphylaxis.

Lying flat is not about preventing a fall. It keeps blood flowing back to the heart.

• Why lie the person flat. Many people assume this is to stop someone hurting themselves if they faint. The real reason is far more serious. When blood pressure has collapsed, sitting or standing upright reduces the blood returning to the heart, and this can bring on a cardiac arrest. An Australian review describes avoiding an upright position as one of the most important parts of treatment.⁴⁸ That is why ASCIA says to lay the person flat and not let them stand or walk, and to hold young children flat, not upright.^49,50
• The one exception: breathing difficulty. If breathing is difficult, ASCIA advises letting the person sit with their legs stretched out in front of them, rather than lying down. Someone who is unconscious or pregnant should be placed in the recovery position, on their left side if pregnant.⁴⁹
• Even after they seem better. ASCIA advises that the person should not stand, walk or be held upright, even if they appear to have recovered. Do not help them up to walk to a car or an ambulance.⁴⁹
• Why adrenaline, and why straight away. In fatal reactions, the median time to respiratory or cardiac arrest has been about 30 minutes for foods, 15 minutes for insect venom and just 5 minutes for medicines given in hospital.⁴⁸ Adrenaline works quickly to reduce throat swelling, open the airways, and support the heart and blood pressure, so it acts against every one of these dangers at once.⁵¹ Delays can be fatal, which is why ASCIA’s rule is “if in doubt, give adrenaline”. Side effects such as a racing heart, shakiness and pale skin are common and wear off.⁵¹
• Why call 000 even if adrenaline works. Symptoms can return hours later in a second wave, known as a biphasic reaction. Studies put this at between 2% and 20% of cases, and people should be observed in an emergency department for at least six hours after a reaction.⁴⁸ Further adrenaline may be given if there is no response after five minutes.⁵⁰

Getting a Diagnosis: Different Tests for Different Conditions

Because the family is so varied, there is no single test for mast cell disease. Which tests make sense depends on which condition is suspected.

The MCAS criteria

The most widely used criteria for MCAS, published by an international expert group in 2012 and updated since, require all three of the following:^1,3

• Typical signs and symptoms of mast cell mediator release, affecting at least two organ systems, usually in recurrent, severe episodes.
• Objective lab evidence, preferably a rise in blood tryptase during an episode of at least 20% above the person’s baseline plus 2 ng/mL (the “20% + 2” rule).
• A response to treatment that blocks mast cell mediators, such as antihistamines.

ASCIA, the peak body for clinical immunology in Australia and New Zealand, endorses these criteria and notes that MCAS should be a diagnosis made after other conditions with overlapping features have been ruled out.³

Tryptase: one test, two jobs

Tryptase does two different jobs in mast cell medicine. A baseline level, taken when you are well, reflects how many mast cells you have and is the key number for mastocytosis and HαT. An acute level, taken during or soon after an episode, shows whether mast cells have just released their contents, which is the key number for MCAS and anaphylaxis.^3,52

After an episode, tryptase peaks within about four hours and returns to normal by around 24 hours.³ ASCIA advises that the ideal acute sample is taken between 30 minutes and two hours after an episode, though it can still be useful up to six hours afterwards, with a baseline sample taken at least 24 hours after all symptoms have settled.^3,52

What tests are available in Australia

ASCIA states that tryptase is the most validated and accessible test in Australia and New Zealand for MCAS. Urine histamine metabolites are available and useful in the investigation of systemic mastocytosis, but have shown little usefulness for MCAS. Several tests used overseas (such as prostaglandin D2 and leukotriene E4 assays) are not generally offered here because cut-off values have not been established.³

Two schools of thought on MCAS

It would be dishonest to present this part of the field as settled. Mastocytosis has firm, internationally agreed criteria,¹⁶ but there are two main approaches to diagnosing MCAS, and they can give very different answers. One 2025 US study of 100 young people with POTS found MCAS in 2% using the strict criteria, 37% using a conservative version of the broader criteria, and 87% using clinical judgement alone.⁵³

• The “consensus-1” approach (the criteria above) is used by the major allergy and immunology bodies, including the American Academy of Allergy, Asthma and Immunology and ASCIA. These groups worry about overdiagnosis, where a person is given an MCAS label without objective evidence, and another treatable condition is then missed.^3,9,35
• The “consensus-2” approach, led by Drs Lawrence Afrin and Gerhard Molderings, uses broader criteria that accept a wider range of mediators and symptom patterns.⁵⁴ This group estimates that MCAS may affect between 4% and 17% of people in the Northern Hemisphere (with German estimates at the top of that range), and argues that strict criteria leave many genuinely unwell people underdiagnosed and untreated.^10,55,56

The consensus-2 group reported in 2026 that, in their view, fears of overdiagnosis have not been realised.⁵⁵ A 2024 review by a large panel of mast cell researchers, including clinicians from the US National Institutes of Health and a patient organisation, acknowledged that big gaps remain in understanding what drives MCAS, and called for more research into mechanisms, better tests and better education for both patients and doctors.³⁵

Whichever criteria a clinician uses, people living with these symptoms deserve careful, respectful investigation.

Related conditions: EDS, POTS and long COVID

Many people in the chronic illness community live with mast cell symptoms alongside hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder, and postural orthostatic tachycardia syndrome (POTS). The evidence on how these conditions relate is genuinely mixed:

• One US review of the records of 195 patients seen for autonomic disorders found MCAS in 31% of those with both POTS and EDS, compared with 2% of those without them.⁵⁷ The 2025 study of young people with POTS described the overlap as firmly established, while showing how heavily the numbers depend on which definitions are used.⁵³
• Other reviewers have concluded that the shared symptoms are vague and overlapping, that a common underlying mechanism has not been shown, and have questioned the evidence for MCAS and hEDS as distinct conditions at all.⁵⁸ ASCIA’s current position is that EDS and POTS should not be used as part of the criteria for diagnosing MCAS.³
• Research on hereditary alpha-tryptasemia found it in 4.9% of people with hypermobility disorders, about the same as the general population, but it may shape a particular subgroup with more mast cell–type symptoms.²³

Mast cell activation has also been proposed as one contributor to long COVID. A small 2023 Italian study gave 14 people with long COVID two antihistamines (fexofenadine and famotidine) for 20 days and compared them with 13 untreated patients. Fatigue, brain fog, gut symptoms and heart rate improved in the treated group, and symptoms cleared completely in 29% of them.⁵⁹ It was a small study, and larger trials are needed.

What Sets Off a Flare

Triggers are highly individual, can change over time, and often stack up. A person who copes with one trigger on a calm day may react strongly when several arrive together, such as heat, poor sleep and a stressful week. In a 2010 survey of 420 people with mast cell disorders run by The Mastocytosis Society (a US patient organisation), most of whom had mastocytosis, heat was the most commonly reported trigger (82%), followed by stress (81%), exercise (63%), alcohol (54%), medications (53%) and odours (48%).^60,61

Important: never stop or avoid a prescribed medicine on your own because it appears on a trigger list. Many people tolerate these medicines well. Talk with your specialist about which, if any, are a concern for you, and about plans for safe premedication before surgery, dental work or scans.^3,62

What Can Help: Managing Mast Cell Activation Disease

Apart from childhood skin mastocytosis, which often fades, and some chronic hives, which can settle over time, most mast cell conditions are long-term and are managed rather than cured. Many people find meaningful relief.^11,26,63 Management usually rests on three pillars: understanding and reducing triggers, medicines that calm mast cells or block their mediators, and caring for the whole person, including brain fog, anxiety and low mood.^3,64 For most people with MCAS and for indolent systemic mastocytosis, life expectancy appears to be close to normal, but quality of life can be significantly affected without the right diagnosis and treatment.^15,65 The rarer advanced forms of systemic mastocytosis are more serious and are managed with haematologists.^3,15

Information itself helps. In a German study of people with MCAS and systemic mastocytosis, quality of life was markedly lower than in healthy people, but those who felt better informed about their condition reported better quality of life.³⁶

Medicines shared across the family (always under medical guidance)

Medication is usually started one step at a time under specialist guidance, and choices are often tailored to the body systems most affected.³ Commonly used options include:

• H1 antihistamines, usually non-sedating, second-generation types such as cetirizine or fexofenadine. These target itch, flushing, hives and some heart and head symptoms.^3,66
• H2 antihistamines, such as famotidine, which act on histamine receptors in the gut and elsewhere and are often combined with H1 blockers.^3,64
• Leukotriene blockers, such as montelukast, used particularly for skin and airway symptoms.^3,39,64
• Mast cell stabilisers, such as sodium cromoglicate (cromolyn) and ketotifen, which aim to reduce how readily mast cells release their contents.^3,64
• Omalizumab, an injected antibody treatment. In MCAS, specialists may consider it when symptoms do not respond to other medicines, and case reports and small case series suggest it can prevent spontaneous anaphylaxis.^9,64 In chronic spontaneous urticaria it is an established second-line treatment.²⁷
• Adrenaline (epinephrine) autoinjectors and an ASCIA Action Plan for Anaphylaxis for anyone at risk of severe reactions.³

It is worth knowing that the research base for treating mediator symptoms is still thin. A systematic review of H1 antihistamines for primary mast cell disorders found only a handful of quality trials and called urgently for more.⁶⁶ That does not mean these medicines do not help, as many people find them life-changing, but it does mean individual responses vary and adjustments often take time.

What is different for each condition

Food and diet: what the evidence says

Diet is one of the most discussed, and most confusing, parts of living with MCAD. ASCIA states that there are currently no evidence-based dietary changes recommended for MCAS, and that low-histamine and low-FODMAP diets, while popular online, have not been tested in well-designed clinical trials.³ Similarly, an expert review of mastocytosis in children notes that general dietary restrictions are not recommended and not necessary in most cases.¹¹

At the same time, many people do identify personal food triggers. A sensible middle path is:

• Keep a food and symptom diary to spot genuine patterns, rather than cutting out whole food groups on suspicion.
• If you trial a low-histamine approach, keep it short and structured, and work with a dietitian experienced in food intolerance so your diet stays nourishing.³
• Favour fresh foods and eat leftovers promptly or freeze them, since histamine levels can rise in some foods, especially fish and meat, as they age.
• Be especially cautious about restriction if you have a history of a difficult relationship with food, or if a child is involved.

Everyday strategies

• Know your triggers, and your limits. Use a diary to identify your personal triggers and the “stacking” effect when several arrive together.⁶²
• Plan for heat. In South Australian summers, cooling strategies, shade, loose breathable clothing and pacing outdoor activity matter. TAMS has a dedicated guide to summer and mast cell disease.¹³
• Be sting-aware. Especially if you have mastocytosis, MMAS or HαT, take care outdoors in warmer months, carry your adrenaline autoinjector if prescribed, and ask your specialist about venom allergy testing if you have ever reacted to a sting.^7,20
• Pace your exercise. Gentle, regular movement often goes down better than intense bursts. Increase slowly and stop before you are overheated.
• Make stress care part of treatment, not an extra. Since stress can directly activate mast cells,⁴² calming the nervous system through rest, breathing practices, gentle yoga, counselling or whatever works for you is a genuine part of management.
• Prepare for medical procedures. Tell your surgeon, anaesthetist, dentist and radiology team about your diagnosis well ahead of time, so a premedication plan can be made with your specialist.⁶²
• Carry your information. An action plan, a list of medicines and known triggers, and your specialist’s contact details make emergencies much easier to manage.
• Look after your mental health. Living with an unpredictable, often invisible condition is hard. Peer support and counselling can make a real difference.⁴¹

Caring for sensitive skin

Skin is often the most visible place mast cell disease shows up, from the brown spots of mastocytosis to the hives of urticaria, and dermatographism is one of the most common examination findings in MCAS.^4,11 Some gentle principles:

• Choose fragrance-free products, and remember that “natural” is not the same as non-triggering. Essential oils and botanical scents can provoke reactions in sensitive people.⁶²
• Introduce one new product at a time and patch test on a small area over a few days.
• Avoid scrubs, exfoliating tools and vigorous towel drying. Pat skin dry, and avoid rubbing any mastocytosis spots, since rubbing can set them off.¹¹
• Use comfortable, lukewarm water rather than hot showers or very cold plunges.
• Choose soft, breathable fabrics, tagless clothing and flat seams to reduce friction.
• Protect skin from strong sun, which is a trigger for some people.⁶²

Finding Care in South Australia

A GP is usually the first step and can refer to a clinical immunology and allergy specialist. If systemic mastocytosis is suspected, a haematologist may become involved.³ Children can be referred to paediatric clinical immunology and allergy specialists.⁷⁰ Specialists vary in their experience with mast cell disorders, so when booking it is reasonable to ask whether a clinic sees people with mast cell conditions.

Support and Resources

A Closing Word

Whether it is a child’s itchy spots, a bone marrow diagnosis, an inherited trait, hives that will not settle, or reactions no one can explain, mast cell activation disease asks a great deal of the people who live with it: constant vigilance, patience with a slow diagnostic process, and the energy to explain an often invisible condition over and over again. If you recognise yourself in these pages, please know that your symptoms are real, that understanding is growing every year, and that there are clinicians and communities ready to walk alongside you.

Be gentle with your body. It is not your enemy; its first responders are simply working a little too hard.

Sources

1. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–225. https://pmc.ncbi.nlm.nih.gov/articles/PMC3224511
2. Valent P, Hartmann K, Bonadonna P, et al. Global classification of mast cell activation disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM Consortium. J Allergy Clin Immunol Pract. 2022;10(8):1941–1950. doi:10.1016/j.jaip.2022.05.007
3. Australasian Society of Clinical Immunology and Allergy (ASCIA). Position Paper: Diagnosis and Investigation of Mast Cell Activation Disorders and Syndrome. Updated December 2025. https://allergy.org.au/hp/papers/testing-for-mast-cell-activation-disorders-and-syndrome
4. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207–215. doi:10.1016/j.amjms.2016.12.013
5. Afrin LB, Butterfield JH, Raithel M, Molderings GJ. Often seen, rarely recognized: mast cell activation disease – a guide to diagnosis and therapeutic options. Ann Med. 2016;48(3):190–201. doi:10.3109/07853890.2016.1161231
6. ASCIA. Mastocytosis and Other Mast Cell Disorders: Information for Patients and Carers. 2025. https://allergy.org.au/patients/allergy-testing/mastocytosis
7. TAMS. Hereditary alpha tryptasemia (HαT). https://mastocytosis.org.au/mast-cells-activation-disorders/hereditary-alpha-tryptasemia/
8. Huang X, Lan Z, Hu Z. Role and mechanisms of mast cells in brain disorders. Front Immunol. 2024;15:1445867. doi:10.3389/fimmu.2024.1445867
9. Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883–896. doi:10.1016/j.jaci.2019.08.023
10. Taumann W, Molderings GJ. Cardiovascular manifestations in mast cell activation disease: key insights for cardiologists and angiologists. Front Cardiovasc Med. 2025;12:1705201. doi:10.3389/fcvm.2025.1705201
11. Lange M, Hartmann K, Carter MC, et al. Molecular background, clinical features and management of pediatric mastocytosis: status 2021. Int J Mol Sci. 2021;22(5):2586. doi:10.3390/ijms22052586
12. Brockow K, Plata-Nazar K, Lange M, Nedoszytko B, Niedoszytko M, Valent P. Mediator-related symptoms and anaphylaxis in children with mastocytosis. Int J Mol Sci. 2021;22(5):2684. doi:10.3390/ijms22052684
13. The Australasian MCAD Society (TAMS). https://mastocytosis.org.au
14. Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–139. doi:10.1016/j.jaci.2014.11.035
15. Jaishankar D. Systemic mastocytosis. Medscape Reference (Besa EC, chief editor). Updated 30 May 2023. https://emedicine.medscape.com/article/203948-overview
16. Girton M, Aguilera N. Systemic mastocytosis. PathologyOutlines.com (author update 7 August 2023). https://www.pathologyoutlines.com/topic/bonemarrowsystemicmastocytosis.html
17. CheckRare. Long-term outcomes from the PIONEER study in patients with indolent systemic mastocytosis (interview with Dr Tsewang Tashi, Huntsman Cancer Institute). https://checkrare.com/long-term-outcomes-from-the-pioneer-study-in-patients-with-indolent-systemic-mastocytosis/
18. HCPLive. Advancing treatment in indolent systemic mastocytosis: updates at EAACI 2025. https://www.hcplive.com/insights/advancing-treatment-in-indolent-systemic-mastocytosis-updates-at-eaaci-2025
19. Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis. 2010;69(10):1838. PMID 20570833. https://ard.bmj.com/content/69/10/1838
20. Siebenhaar F, Nojarov N, Pyatilova P. Mastocytosis and insect venom allergy: a special relationship. Allergo J Int. 2026;35(1):1–7. doi:10.1007/s40629-025-00361-9
21. TAMS. Mast cell activation syndrome (MCAS). https://mastocytosis.org.au/mast-cell-activation-syndrome-mcas/
22. Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48:1564–1569. doi:10.1038/ng.3696
23. Vazquez M, Chovanec J, Kim J, et al. Hereditary alpha-tryptasemia modifies clinical phenotypes among individuals with congenital hypermobility disorders. HGG Adv. 2022;3(2):100094. doi:10.1016/j.xhgg.2022.100094
24. Lyons JJ, Chovanec J, O’Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021;147(2):622–632. doi:10.1016/j.jaci.2020.06.035
25. Puxkandl V, Aigner S, Hoetzenecker W, Altrichter S. Hereditary alpha tryptasemia: elevated tryptase, female sex, thyroid disorders, and anaphylaxis. Front Allergy. 2024;5:1461359. doi:10.3389/falgy.2024.1461359
26. ASCIA. Chronic Spontaneous Urticaria (CSU): Information for Patients and Carers. Updated 2024. https://allergy.org.au/patients/skin-allergy/urticaria-hives-chronic
27. Saed Aldien A, Ben-Shoshan M, Netchiporouk E. Managing chronic spontaneous urticaria. CMAJ. 2025;197(41):E1397.
28. Trajkova V, Mitrevska NT, Kocatürk E, et al. Clinical and autoimmune characteristics associated with angioedema in patients with chronic spontaneous urticaria. Explor Asthma Allergy. 2025;3:1009101. doi:10.37349/eaa.2025.1009101
29. Sartorio S, Rivolta F, Tedeschi A, et al. Demographic and clinical characteristics of chronic histaminergic angioedema and chronic urticaria with angioedema: a multicenter Italian experience. Eur Ann Allergy Clin Immunol. 2026;58(4):173–179. doi:10.23822/EurAnnACI.1764-1489.411
30. ASCIA. Angioedema: Information for Patients and Carers. https://allergy.org.au/patients/skin-allergy/angioedema
31. Bernstein JA, Cremonesi P, Hoffmann TK, et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med. 2017;10:15. doi:10.1186/s12245-017-0141-z
32. ASCIA. Hives (urticaria): Information for Patients and Carers. https://allergy.org.au/patients/skin-allergy/urticaria-hives
33. ASCIA. Idiopathic Anaphylaxis: Information for Patients and Carers. https://allergy.org.au/patients/about-allergy/idiopathic-anaphylaxis
34. Valent P, Akin C, Nedoszytko B, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci. 2020;21(23):9030. doi:10.3390/ijms21239030
35. Castells M, Giannetti MP, Hamilton MJ, et al. Mast cell activation syndrome: current understanding and research needs. J Allergy Clin Immunol. 2024;154(2):255–263. doi:10.1016/j.jaci.2024.05.025
36. Schmidt TJ, Sellin J, Molderings GJ, Conrad R, Mücke M, et al. Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome. Orphanet J Rare Dis. 2022;17:295. doi:10.1186/s13023-022-02439-x
37. Hamilton MJ. Mast cell activation syndrome and gut dysfunction: diagnosis and management. Curr Gastroenterol Rep. 2024;26(4):107–114. doi:10.1007/s11894-024-00924-w
38. Mast Cell Action. Symptoms of MCAS (written by the charity’s medical communications and education lead, with references). https://www.mastcellaction.org/symptoms
39. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10
40. Jendoubi F, Severino-Freire M, Negretto M, Arbus C, Paul C, Bulai Livideanu C. Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. Orphanet J Rare Dis. 2021;16:118. doi:10.1186/s13023-021-01747-y
41. Nicoloro-SantaBarbara J, Lobel M, Wolfe D. Psychosocial impact of mast cell disorders: pilot investigation of a rare and understudied disease. J Health Psychol. 2017;22(10):1277–1288.
42. Kempuraj D, Mentor S, Thangavel R, et al. Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer’s disease. Front Cell Neurosci. 2019;13:54. doi:10.3389/fncel.2019.00054
43. Severance S, Daylor V, Petrucci T, Gensemer C, Patel S, Norris RA. Hypermobile Ehlers-Danlos syndrome and spontaneous CSF leaks: the connective tissue conundrum. Front Neurol. 2024;15:1452409. doi:10.3389/fneur.2024.1452409
44. Westerman M, Kafkas A, Parry-Jones A, Strong S, Retzler C, Hallam G. Neurobiological and neuropsychological disturbance in EDS. Front Neurol. 2025;16:1648702. doi:10.3389/fneur.2025.1648702
45. ASCIA. Anaphylaxis: Information for Patients and Carers. https://allergy.org.au/patients/about-allergy/anaphylaxis
46. Speech and Language Therapy Department, Queen Victoria Hospital NHS Foundation Trust. Acid reflux (patient leaflet no. 0532, 2016). https://www.qvh.nhs.uk/download/acid-reflux
47. ASCIA. Vocal Cord Dysfunction: Information for Patients and Carers. https://allergy.org.au/patients/allergic-rhinitis-hay-fever-and-sinusitis/vocal-cord-dysfunction
48. Kirkbright SJ, Brown SGA. Anaphylaxis: recognition and management. Aust Fam Physician. 2012;41(6):366–370. https://www.racgp.org.au/getattachment/d255c9f9-d439-4733-ad26-46801cfbb9a0/Anaphylaxis-recognition-and-management.aspx
49. ASCIA. How to position a person having anaphylaxis. https://allergy.org.au/hp/anaphylaxis/positioning
50. ASCIA. First Aid for Anaphylaxis. https://allergy.org.au/hp/anaphylaxis/first-aid-for-anaphylaxis
51. ASCIA. Adrenaline for Severe Allergies: Information for Patients and Carers. https://allergy.org.au/patients/allergy-treatments/adrenaline-for-severe-allergies
52. Beyens M, Toscano A, Ebo D, Gülen T, Sabato V. Diagnostic significance of tryptase for suspected mast cell disorders. Diagnostics. 2023;13(24):3662. doi:10.3390/diagnostics13243662
53. Yao L, Subramaniam K, Raja KM, et al. Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients; prevalence, overlap and response to therapy depends on the definition. Front Neurol. 2025;16:1513199. doi:10.3389/fneur.2025.1513199
54. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2”. Diagnosis (Berl). 2021;8(2):137–152. doi:10.1515/dx-2020-0005
55. Afrin LB, Blitshteyn S, Bluestein LS, et al. Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years. Diagnosis (Berl). Published online 4 June 2026. doi:10.1515/dx-2026-0016
56. Raithel M, Homann J, Rieker R, Molderings GJ. Gastrointestinal manifestations of systemic mast cell activation disease. Z Gastroenterol. 2025;63(2):155–168. doi:10.1055/a-2468-5553
57. Wang E, Ganti T, Vaou E, Hohler A. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome. Allergy Asthma Proc. 2021;42(3):243–246. doi:10.2500/aap.2021.42.210022
58. Kucharik AH, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273–297. doi:10.1007/s12016-019-08755-8
59. Salvucci F, Codella R, Coppola A, et al. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation. Front Cardiovasc Med. 2023;10:1202696. doi:10.3389/fcvm.2023.1202696
60. Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38(3):469–481. doi:10.1016/j.iac.2018.04.002 (reporting Jennings S, et al. The Mastocytosis Society survey on mast cell disorders. J Allergy Clin Immunol Pract. 2014;2:70–76)
61. Russell N, Jennings S, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: part 2 – patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7(4):1157–1165.
62. UK Mastocytosis Support Group. What triggers mast cells? https://ukmasto.org/?p=1043
63. Allergy & Asthma Network. What is Mast Cell Activation Syndrome (MCAS)? https://allergyasthmanetwork.org/mast-cell-diseases/mcas/
64. Akin C, Butterfield JH, Castells M, Lyons JJ. Management of indolent mastocytosis and mast cell activation syndrome: a clinical yardstick. Ann Allergy Asthma Immunol. 2025;135(4):466–477. doi:10.1016/j.anai.2025.06.032
65. Afrin LB. Presentation, diagnosis, and management of mast cell activation syndrome. In: Mast Cells: Phenotypic Features, Biological Functions and Role in Immunity. Nova Science Publishers; 2013:155–232.
66. Nurmatov UB, Rhatigan E, Simons FER, Sheikh A. H1-antihistamines for primary mast cell activation syndromes: a systematic review. Allergy. 2015;70(9):1052–1061. doi:10.1111/all.12672
67. Gotlib J, Castells M, Oude Elberink H, et al. Avapritinib versus placebo in indolent systemic mastocytosis (PIONEER). NEJM Evid. 2023;2. doi:10.1056/EVIDoa2200339
68. Blueprint Medicines (Sanofi). Four-year avapritinib data in indolent systemic mastocytosis, reported in European Pharmaceutical Review. https://www.europeanpharmaceuticalreview.com/news/blueprints-rare-disease-drug-ayvakit-shows-long-term-benefit/1131769.article
69. Pharmaceutical Benefits Scheme. Medicine status: midostaurin (Rydapt), advanced systemic mastocytosis (information current at 1 October 2026). https://www.pbs.gov.au/medicinestatus/document/1303.html
70. ASCIA. Locate a Specialist: South Australia (accessed 14 October 2026). https://allergy.org.au/patients/locate-a-specialist/sa
71. Royal Adelaide Hospital. Clinical Immunology and Allergy (accessed 14 October 2026). https://www.rah.sa.gov.au/services-clinics/clinical-immunology-allergy
72. SA Health, Southern Adelaide Local Health Network. Allergy and Clinical Immunology Service, Flinders Medical Centre: service descriptions in current position listings. https://careers.sahealth.sa.gov.au/caw/en/job/909089/adult-registrar-allergy-clinical-immunology
73. Allergy & Anaphylaxis Australia. National Allergy Helpline. https://allergyfacts.org.au/contact-us
74. Mast Cell Action (UK). https://www.mastcellaction.org
75. The Mast Cell Disease Society, Inc. https://tmsforacure.org